RT Journal Article
SR Electronic
T1 Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 54
OP 61
DO 10.3899/jrheum.180141
VO 94
A1 Deepak R. Jadon
A1 Vinod Chandran
A1 Carmel Stober
A1 Alexis Ogdie
A1 April W. Armstrong
A1 Kristina Callis Duffin
A1 Dafna D. Gladman
A1 Philip S. Helliwell
A1 Denis O’Sullivan
A1 Maarten de Wit
A1 Oliver FitzGerald
A1 Christopher T. Ritchlin
YR 2018
UL http://www.jrheum.org/content/94/54.abstract
AB The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Collaborative Research Network (CRN) is an endeavor that aims to address gaps in the knowledge of the etiopathogenesis and management of psoriatic disease by best using the large community of experienced investigators who are already collecting rich clinical phenotype data and biologic samples using validated techniques. Exemplar rheumatology and dermatology projects will inform strategies to implement the CRN, while input and funding from government organizations, charities, and industry will shape the CRN. The key immediate priorities to establish the CRN are discussed herein and include (1) strategies for building infrastructure to collect and store biosamples and associated clinical data, (2) best practices for sample collection and storage, (3) approaches to engage the GRAPPA community of investigators and industry to collaborate most effectively on shared priorities, and (4) agreement on a funding strategy. The following 4 CRN candidate flagship research areas were identified: (1) predictors of treatment response in psoriatic arthritis (PsA) and cutaneous psoriasis (PsC) to permit personalized and stratified medicine approaches; (2) predictors of structural damage and disease severity, linking with the existing PsA BioDAM project; (3) predictors of PsC progressing to PsA to enable earlier intervention and possibly halt progression to PsA; and (4) comorbidity prevalence and effect on clinical outcomes in psoriatic disease. The collaboration and momentum provided by a GRAPPA-CRN will offer more than the sum of its individual contributing centers. A CRN will permit high-quality research that can more effectively address questions pertinent to patients, clinicians, scientists, industry, and governments.